daGOAT-Guided Prevention of Severe aGVHD After Allo-HSCT

Phase 3 Not yet recruiting 438 enrolled Institute of Hematology & Blood Diseases Hospital, China

RandomizedParallel-groupOpen-labelPrevention

Summary

This study aims to evaluate the efficacy of prophylactic ruxolitinib in adult patients at intermediate-to-high risk of severe acute GvHD, as predicted by the daGOAT model.

Timeline

Start: 2026-06-01
Primary completion: 2027-12-31
Completion: 2028-06-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ruxolitinib	Small molecule	5 mg	Oral

daGOAT-Guided Prevention of Severe aGVHD After Allo-HSCT

Summary

Timeline

Drugs

Indications